Key facts

Specialist primary healthcare infrastructure fund
MedicX Fund is a leading investor in modern purpose-built primary healthcare properties leased to doctors and the NHS.

Investment in primary health and social care facilities is a key UK Government priority – new buildings provide people with modern integrated primary care services.

The Fund’s investment objective is to achieve rising rental income and capital growth from the property portfolio.

The key objective of the Fund is to increase net income over time to support a rising dividend and provide capital growth.


Company Website

Financial Calendar

Recent Broker notes

BarChart Indicators

Recent Market news

MedicX Fundamentals (MXF)

A bit of juggling by Blackrock.

Can't see why such a drop in sp. Anyone got a clue?

No. Seems odd, though coincidentally the recent decline in the sp seems to have happened shortly after MXF changed to REIT status. I wonder if institutional investors had to rethink their exposure?

BlackRock > 5%

MedicX Fund Positioning for continuing growth

Liberum Capital today initiates coverage of MedicX Fund Ltd (LON:MXF) with a buy investment rating and price target of 90p.

Broker link updated in the header.

Results for the year ended 30 September 2018

BUILDING A BRIGHTER FUTURE FOR PRIMARY HEALTHCARE INVESTMENT



MedicX Fund is a leading investor in modern purpose-built primary healthcare properties. Our investment supports the transformation of the primary healthcare estate in the United Kingdom and Republic of Ireland.

FINANCIAL HIGHLIGHTS AND KEY ACHIEVEMENTS

Another year of strong performance, reflecting progress and achieving notable milestones.

FINANCIAL RESULTS

· 11.4% increase in EPRA13 earnings per Ordinary Share, from 3.5p per share to 3.9p per share;

· 14.8% total return on EPRA NAV2 for the financial year (2017: 12.7%);

· 6.9% increase in EPRA NAV per share, from 76.5p per share to 81.8 pence per share;

· Continued increase in rent receivable, up 8.6% to £40.3 million (2017: £37.1 million);

· Profit before tax was £49.1 million for the year; 47.4% higher than 2017 (£33.3 million);

· 10.0% increase in annualised rent roll1,14 from £40.0 million to £44.0 million;

· 89.4% (2017: 89.7%) of rent roll was directly from or reimbursed by the NHS11, Irish GPs or HSE12;

· EPRA cost ratios reduced year on year to 18.4% from 19.8% with the investment adviser fee reduction due to reduce this further; and

· Independent expert determination of March 2015 rent review at Clapham increase of 35% (equating to a compounded 10.54% per annum increase over the applicable 3 year rent review period).

INVESTMENTS

· 18.6% increase in the value of the property portfolio to £806.7 million1,4. This is as a result of £99.2 million of capital investment to acquire standing let properties and fund developments through forward funding schemes, less £5.3 million of disposals and a £32.3 million net valuation gain;

· Net Initial Yield of UK assets 4.85% at 30 September 2018 (2017: 5.08%);

· £80.3 million of new committed investments in UK and Republic of Ireland, since 1 October 2017, with a weighted average cash yield of 4.63% together with the acquisition of three sites for £5.3 million in anticipation of new schemes;

· Competed £63.8 million corporate portfolio acquisition of 12 fully let primary care centres with 10 of the properties having an average age of 5.5 years, WAULT of 14.2 years and an average lot size of £5.3m; and

· Strong pipeline of approximately £144 million (2017: £175 million) of further acquisition opportunities including projects with a value of £69 million in solicitors' hands1 (2017: £100 million).

INVESTMENT ADVISER FEE REDUCTION

· The Investment Adviser has agreed a reduction in its fees to reflect the change in the Company's dividend policy and to reduce its costs. Effective from 1 October 2018, the performance fee was abolished, and the investment adviser fee will be £0.5 million per annum lower until the portfolio reaches £1 billion with tapering savings between £1 billion and £1.25 billion. This immediately increases next year's earnings by 0.113 pence per share.

CAPITAL MANAGEMENT

· Quarterly dividend of 1.51p per share announced on 1 November 20185; total dividends of 6.04p per Ordinary Share for the year or 7.4% dividend yield on a share price of 82.0 pence per share at 30 September 20186 (2017: total dividends of 6.0p per Ordinary Share; 6.6% dividend yield);

· Total drawn debt facilities of £446.1 million1 with a weighted average fixed rate cost of debt of 4.26% and an average unexpired term of 12.3 years, compared with 4.29% and 12.7 years for the prior year; and

· Net debt of £430.0 million equating to 52.6% adjusted gearing at 30 September 2018 (30 September 2017: £340.7 million; 49.5%)1,7.

UPDATE ON DIVIDEND POLICY

As announced in May 2018, the Company intends to declare a fully covered dividend for the 2019 financial year onwards.

This new policy of paying a fully covered dividend is intended to free up additional funds for the Group to invest in attractive opportunities, and enable it to deliver superior capital growth over time from a sector which continues to demonstrate attractive growth prospects.

Going forward, the Company intends to continue to pay shareholders the dividend on a quarterly basis, in March, June, September and December of each financial year and on a growing covered basis.

Subject to unforeseen circumstances and based on the current performance, the Directors are targeting dividends of 3.80p per share for the financial year ended 30 September 2019.

more.....

Peel Hunt Hold 75.93 72.00 76.00 Upgrades

Liberum Capital Buy 75.93 90.00 Reiterates

RECOMMENDED ALL-SHARE MERGER OF PHP & MEDICX FUND